HE molecular and cellular mechanisms underlying vascular dysfunction during cerebral vasospasm after subarachnoid hemorrhage (SAH) remain a topic of intense scrutiny and discussion. 6 Two hypotheses concerning the pathogenesis of cerebral vasospasm that have received increasing support are 1) the activation of protein kinase C (PKC) is a critical component of spastic constriction, 15, 19, 25, 29 and 2) the loss of calcitonin gene-related peptide (CGRP)-mediated relaxation contributes to and/or aggravates spastic constriction. 5, [21] [22] [23] Careful examination of both of these mechanisms is therefore warranted, and the possibility that these mechanisms interact should be considered.
ߜ Increasing evidence suggests that disturbances in the modulatory influence of the vasoactive peptide, calcitonin gene-related peptide (CGRP), contribute to the pathogenesis of cerebral vasospasm after subarachnoid hemorrhage (SAH). However, only limited success has been achieved in trials attempting to ameliorate vasospasm by modifying CGRP function. To better understand the potential utility of targeting CGRP-mediated relaxation, it is important both to identify the interactions CGRP may have with other elements of the vasospastic response and to characterize the mechanisms through which CGRP elicits vasodilative effects. The present studies examined the effects of CGRP on vascular responsiveness using tension measurements of ring strips of rabbit basilar artery maintained in vitro. Pretreatment of vessels with CGRP (100 nM) inhibited vasoconstrictor responses to the potent protein kinase C (PKC) activator, phorbol 12,13-dibutyrate (PDB). This particular contractile response was selected because PKC-mediated vasoconstriction is a critical component of the vasospastic response after SAH. In a posttreatment paradigm, CGRP was also found to reverse established constriction responses to PDB (2 nM) and histamine (3 M) in a dose-dependent manner.
When tested against the maximum effective dose of PDB (30 nM) in the posttreatment paradigm, CGRP (100 nM) did not elicit significant relaxation. However, after washing both of these drugs out of the test chamber, a persistent effect of CGRP was revealed: the decay of PDB-induced contraction was accelerated in vessels that had previously been treated with CGRP. These findings indicate that CGRP elicits both immediate and sustained influences on contractile responses mediated by PKC.
Finally, two potential mechanisms for the vascular response to CGRP were examined. Adenosine triphosphate (ATP)-sensitive K + channels do not appear to participate in CGRP-mediated dilation; inhibitors of these channels, glibenclamide and tolbutamide, did not block CGRP-induced relaxation. In contrast, a possible role for the nucleotide cyclic adenosine monophosphate (cAMP) in the vascular response to CGRP was indicated by the dose-dependent elevation of cAMP levels by CGRP.
Together these studies indicate that CGRP can modulate the contractile response to PKC activation. These effects are associated with increases in the levels of cAMP, but occur independently of fluxes through ATP-sensitive K + channels.
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T contraction of the cerebral vasculature and implicate this mechanism in the pathophysiology of vasospasm.
The state of cerebrovascular tone at any given time reflects the combined activity of a variety of constrictor and dilator substances. Under physiological conditions, the 37-amino acid peptide 1 CGRP is one of the most prominent vasodilators in the cerebral circulation. 22, 23 This peptide originates from perivascular nerves 8, 9, 11 that provide a longitudinally oriented network of fibers around large arteries in the circle of Willis. 3, 4 Also, CGRP has been shown to elicit dose-dependent relaxation in ring segments of basilar artery precontracted with prostaglandin F 2␣ or 5-hydroxytryptamine, but not in rings precontracted with elevated potassium. 10 In perivascular nerves CGRP-like immunoreactivity disappears rapidly in experimental models of SAH, but reappears 1 or 2 months later. 5, 23 These findings demonstrate that CGRP is a potent vasodilator in the cerebral circulation and that a disturbance in CGRP activity could contribute to cerebral vasospasm.
Interactions between vascular responses involving PKC and CGRP therefore may possess differential importance under physiological and pathophysiological conditions. 3, 15, 16, [21] [22] [23] 25, 29 As a first step toward understanding this issue, the present studies examined the effects of CGRP on constrictor responses mediated by PKC. In addition, the mechanistic basis for CGRP-mediated vasoactivity was evaluated.
Materials and Methods

Preparation of the Basilar Artery and Tension Recording
New Zealand White male rabbits, each weighing 2.8 to 3.5 kg, were anesthetized by intramuscular injection of ketamine (50mg/ kg) and xylazine (5 mg/kg). After transoral intubation, the rabbits were paralyzed with pancuronium bromide (0.08 mg/kg) and ventilated with a respirator. While the heart was still beating, each animal was perfused intracardially with 100 ml of aerated (95% O 2 /5% CO 2 ) modified Krebs' solution (in mM: NaCl 120; KCl 4.5; MgSO 4 1.0; NaHCO 3 27.0; KH 2 PO 4 1.0; CaCl 2 2.5; and dextrose 10.0) at room temperature during exsanguination from the left femoral artery. Basilar arteries were dissected free under microscopic view after the brain stem was removed. According to established methods, 7 four basilar artery rings, each 3 mm in length, were prepared from each animal. Each ring was suspended between two L-shaped, silicon-coated rods in an organ bath with 10 ml working volume and placed in an isometric tension set-up. Isometric tension was recorded using a force-displacement transducer, a polygraph, and a chart recorder for later analysis.* The resting tension was adjusted to 400 mg and the preparations were allowed to equilibrate at 37˚C for 60 minutes prior to each experiment. A standard challenge dose of KCl (40 mM) elicited constriction, which was defined as 100% for the purposes of the study.
Drug Preparation
Stock solutions of phorbol 12,13-dibutyrate (PDB) and glibenclamide were made by dissolving the drugs in dimethyl sulfoxide (DMSO). Tolbutamide was dissolved in ethanol. † To minimize the effects of vehicle, the concentrations of DMSO and ethanol were less than 0.01% and 0.5%, respectively. At these concentrations, DMSO and ethanol had no effect on the contractile ability of smooth muscle cells. Both CGRP and histamine were dissolved in double-distilled water. The drugs were further diluted in modified Krebs' solution before use, so that volumes of less than 0.2 ml were added to the organ baths.
Assays for Cyclic Adenosine Monophosphate
Rabbit basilar artery was obtained as described above. The CGRP (1, 10, and 100 nM) was applied for 3 minutes after the arterial strips had been equilibrated for 1 hour at 37˚C, and the reaction was halted by soaking the strips in ice-cold acidic ethanol (1 ml of 1 N HCl/100 ml ethanol). The strips were then homogenized in the same solution using a glass homogenizer. The homogenate was centrifuged and the pellet was used for assay of protein levels. 2 The supernatant was dried by heating to 50˚C under a stream of nitrogen gas. Samples were assayed for cyclic adenosine monophosphate (cAMP) using radioimmunoassay kits. ‡
Statistical Analysis
The values measured are expressed as mean Ϯ standard error of the mean. Differences between means within each experiment were evaluated by analysis of variance. If significant differences were demonstrated, Student's paired or unpaired t-test was used to determine which pairs of means were significantly different; p values less than 0.05 were considered significant.
Results
Contraction Induced by PDB and the Relaxant Effect of CGRP
The vasoconstrictive action of PDB was examined in rings of rabbit basilar artery in the presence and in the absence of 100 nM CGRP. As shown in Fig. 1A , PDB (1 to 30 nM) elicited concentration-dependent contractions. Concentrations of PDB of less than 1 nM failed to evoke contraction even 30 minutes after application. Concentrations of PDB of greater than 100 nM elicited a decrease in tension. The effect of CGRP pretreatment on PDB-induced contraction was examined by applying CGRP (100 nM) for 5 minutes before PDB application and for the remainder of the experiment (Fig. 1B) . Application of 100 nM CGRP significantly decreased the basal tone of ring strips immediately after application (Ϫ5.3 Ϯ 0.6% of KCl-induced contraction, p Ͻ 0.01, six samples), and inhibited the PDB-induced contraction. The concentration-response curve for PDB-induced contraction was shifted to the right in the presence of CGRP and the maximum amplitude of contraction was also reduced significantly (Fig. 1C) . The maximum contractions were 82.7% Ϯ 7.2% (six samples) and 112.8% Ϯ 9.6% (six samples) of KCl-induced contraction in the presence and in the absence of CGRP, respectively (p Ͻ 0.01). The E C 50 values for PDB-induced contraction were 5.6 Ϯ 0.1 nM and 3.1 Ϯ 0.6 nM in the presence and in the absence of 100 nM CGRP, respectively (p Ͻ 0.01, six samples for each condition).
Effects of CGRP on Contractions Induced by PDB, K + , and Histamine
The effects of CGRP on contractions induced by PDB, high K + concentration, or histamine were examined in rings of rabbit basilar artery (Fig. 2) . Each of these constricting agents elicited sustained and stable contractions.
The relative tensions elicited by 2 nM PDB or 3 M histamine were 64.6% Ϯ 9.6% (seven samples) and 115.4% Ϯ 1.5%, respectively, of the contraction elicited by high K + concentrations (six samples for each condition). The CGRP was applied in a cumulative manner after the contraction induced by each agent had reached a plateau. Contractions induced by PDB (2 nM) or histamine (3 M) were reversed by application of CGRP in a concentrationdependent manner. In contrast, the contractile response to a high K + level was only slightly reversed, even at a concentration of 100 nM CGRP (Fig. 2) .
Effects of CGRP on Maximum Contraction Induced by PDB
The effect of CGRP was examined in ring strips of rabbit basilar artery precontracted with 30 nM PDB; this concentration of PDB provokes a maximum contraction. Application of 10 nM CGRP did not modify the amplitude of the contraction induced by 30 nM PDB. However, after washing both drugs out of the chamber, the recovery of arterial strips was significantly faster in strips that had been treated with 10 nM CGRP. As shown in Table 1 , the time required for the tension to recover to 50% of baseline levels was significantly briefer in CGRP-treated strips. When 100 nM CGRP was applied to a vessel in which a PDB (30 nM)-induced contraction had been established, it produced a small relaxation that did not achieve statistical significance (4.5% Ϯ 4.1%). When both PDB and CGRP were removed from the chamber, the time delay to 100% relaxation was significantly shorter in the 100 nM CGRP-treated group than in the 10 nM CGRP-treated group (Fig. 3) .
Effect of Glibenclamide and Tolbutamide on CGRPInduced Relaxation
It has been reported that the activation of adenosine triphosphate (ATP)-sensitive K + channels is involved in CGRP-induced relaxation. 18 To investigate this issue, the effects of two blockers of the ATP-sensitive K + channel (glibenclamide and tolbutamide) on 10 nM CGRPinduced relaxation were examined in arterial rings precontracted with 2 nM PDB. Glibenclamide (1 M) was applied 3 minutes before PDB and for the remainder of the experiment, and did not modify the amplitude of the con-tractile response to 2 nM PDB. Glibenclamide also failed to modify the amount of relaxation elicited by 10 nM CGRP (Fig. 4) . The amounts of relaxation were 80.9% Ϯ 8.3% (seven samples) and 86.0% Ϯ 6.0% (eight samples) in the presence and in the absence of 1 M glibenclamide, respectively. Similar results were obtained with 0.5 mM of the channel blocker, tolbutamide (89.6% Ϯ 10.3%; five samples).
Effect of CGRP on the Accumulation of cAMP
It has been reported that in certain types of arterial tissue CGRP is capable of elevating cellular levels of cAMP.
14 To examine this issue, cAMP levels were measured using a radioimmunoassay. Incubation of arterial strips with CGRP for 3 minutes significantly increased the cellular level of cAMP in a concentration-dependent fashion (Fig. 5 ).
Discussion
The rupture of an intracranial aneurysm and the resultant hemorrhage into the subarachnoid space can lead to a severe form of vascular narrowing known as cerebral vasospasm. The ischemic impact of this profound vascular response can be disabling or even life-threatening. Consequently, substantial effort continues to be directed toward identifying the mechanisms responsible for the initiation and maintenance of vasospasm. The present study investigated interactions between two vascular mechanisms postulated to participate in the pathogenesis of vasospasm. The first of these mechanisms is the potent vasodilative effect of CGRP. 13 The amount of CGRP immunoreactivity in perivascular nerve fibers is severely reduced after experimental SAH. 5, 22 This loss of CGRP activity removes an intrinsic relaxant influence from large cerebral vessels, which can contribute to posthemorrhage vascular narrowing. The loss of CGRP activity by itself, however, appears to be insufficient to fully explain the profound constriction observed in spastic vessels. It is generally accepted that a more active mechanism is necessary to provide the primary contractile force for initiating spastic contraction. The second mechanism of interest in this study, that is, activation of PKC, may provide the contractile force necessary to underlie cerebral vasospasm. 15, 19, 25, 29 Contractions elicited by PKC can be powerful and sustained. 25, 26 In a canine model of SAH this kinase has been shown to be translocated from cytosolic to membrane fractions, an event indicative of activation of the enzyme. 20 Moreover, the time course of PKC activation correlates well with that for narrowing of the basilar artery. 19, 25 Because of the important roles postulated for both CGRP-induced relaxation and PKC-mediated contraction, the present study examined possible interactions between these two vascular mechanisms.
Activation of PKC by the phorbol ester PDB elicited a dose-dependent contraction in ring strips of rabbit basilar artery. Pretreatment with CGRP shifted this doseresponse curve to the right and reduced the size of the maximum response induced by PKC activation. No significant relaxation was induced by CGRP under conditions in which maximum contraction by PDB had been induced. However, some component of the relaxing effect of CGRP did seem to persist, because the rate at which tension was reduced after washing out PDB was more rapid in strips that had been treated with CGRP (Fig. 3 , Table 1 ). These observations suggest that the influence of CGRP on PKC-mediated contractions is at least two-fold. First, a direct relaxant effect of CGRP can directly oppose the constrictor response to PKC activation. Second, CGRP appears to modulate the persistence of PKC-mediated contractions. A change in this latter effect may represent a mechanism through which contractile responses can be potentiated in compromised vessels. In this way, the spasmogenic response to PKC activation could be facilitated by the loss of CGRP activity during cerebral vasospasm.
To further elucidate the mechanisms of CGRP-induced vasorelaxation, the effects of CGRP on contractions elicited by histamine and high K + levels were examined. High K + concentration depolarizes cell membranes and activates voltage-sensitive calcium channels. This series of events results in an increase in both intracellular Ca ++ concentrations and vasoconstriction. In the presence of high K + levels, 10 CGRP elicited only a very limited vasorelaxing effect. This result raises the possibility that membrane hyperpolarization is involved in CGRP-induced relaxation, because the actions of membrane hyperpolarization agents are usually blocked when cells are depolarized by high K + concentrations. 17 Consistent with this notion are the findings of Nelson, et al., 18 who found that the opening of ATP-sensitive K + channels appears to play a primary role in CGRP-induced vasorelaxation in rabbit mesenteric artery. In contrast, the present experiments indicate that the contribution of ATP-sensitive K + channels to CGRP-induced relaxation is negligible. Glibenclamide and tolbutamide, inhibitors of the ATP-sensitive K + channel, were ineffective in reducing relaxations elicited by CGRP (Fig. 4) . These findings suggest that relaxation elicited by CGRP is not mediated by ATP-sensitive K + channels in rabbit basilar artery.
The issue that remains is why CGRP was not effective in reversing contractions induced by high K + concentrations. One possible explanation is that CGRP is only effective against contractions that are relatively small in magnitude. Consistent with this possibility are the current observations that CGRP was relatively weak in reversing strong contractions elicited by high concentrations of PDB or K + . This issue was further examined by testing the effect of CGRP on histamine-induced contractions. Histamine, at a concentration of 3 M, elicits a sustained contraction that is stronger than those elicited by high concentrations of either K + or PDB. However, despite the strength of the contractile response to histamine, CGRP was capable of reversing this contraction in a dose-dependent manner. These results suggest that the reason CGRP is ineffective in inhibiting strong contractions elicited by high K + or PDB levels is not simply a matter of the magnitude of the contractile response.
The basis for the differential effects of CGRP in reversing strong contractile responses may be related to the dissimilarity of mechanisms by which the spasmogens operate. Previous studies have been able to dissociate the absolute magnitude of agonist-induced increases in intracellular calcium in coronary arteries from the magnitude of the contractile response. These effects have been attributed to possible modulation of the sensitivity of smoothmuscle cells to calcium. 27 It is conceivable that a similar modulatory effect could account for the effects of CGRP observed in the present studies. One mechanism by which CGRP might modulate vascular sensitivity to spasmogens is by altering the levels of cAMP. Agents that increase the concentrations of intracellular cAMP have been shown to decrease the sensitivity of vascular smooth-muscle cells to spasmogens. 27 Using simultaneous recordings of intracellular Ca ++ concentrations and force development, Shafiq, et al., 27 demonstrated that the decreases in force elicited by cAMP-inducing agents were disproportionately large compared to the decreases in intracellular Ca ++ . The present studies demonstrated that CGRP increased the cellular levels of cAMP in a concentration-dependent manner (Fig. 5 ). Together these results suggest that cAMP elevation may account for the vasorelaxing ability of CGRP in rabbit basilar artery. The concept that treatments which elevate cAMP are effective in reversing vasospasm is supported by evidence that other cAMP-elevating agents, such as papaverine, are also potent vasodilators under these conditions.
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Conclusions
Interactions between two fundamental mechanisms contributing to spastic cerebrovascular responses were examined. The vasoactive peptide CGRP is capable of attenuating both early and late components of the contractile response to PKC activation. The loss of a tonic relaxant influence of CGRP during vasospasm may contribute directly to increased tone. In addition, enhanced vascular sensitivity to spasmogens may result from the loss of a modulatory influence of CGRP on contractile activity. The capacity of CGRP to modulate contractile responses under physiological conditions does not appear to be the result of increased fluxes through ATP-sensitive K + channels, but may be due to the elevation of intracellular cAMP. 
